Clinical Trial Update: Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women [Phase 1]

View source ↗

Summary

Phase 1 trial comparing bioavailability of preservative-free Makena® injections given intramuscularly by manual injection versus subcutaneously via an auto-inje…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers
• Postmenopausal Conditions

Drugs mentioned

• Makena® (hydroxyprogesterone caproate injection, 250 mg/mL) (hydroxyprogesterone caproate)

Snippet

Sponsor: AMAG Pharmaceuticals, Inc. | Conditions: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women | Phase 1 | Status: COMPLETED | Results posted: 2018-11-30